Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MYC suppression through innovative chemistry

Project description

Novel MYC-targeting peptide for cancer therapy

MYC is a transcription factor that regulates cell growth and division. It is overactivated in more than half of human cancer types, driving uncontrolled proliferation. Despite its importance, MYC has long been considered ‘undruggable’ because of its complex structure and interactions. The ERC-funded MYSTIC project builds on a novel cell-penetrating protein called HeloMYC that inhibits MYC activity inside cancer cells. HeloMYC contains chemical modifications that endow it with high-stability and intracellular action. The project will complete the preclinical development of HeloMYC and proceed with commercialisation, paving the way for a new approach to treating MYC-driven cancers.

Objective

"MYSTIC aims to revolutionize cancer treatment by advancing HeloMYC, a novel cell-penetrating protein therapeutic that targets the oncogenic transcription factor MYC. Developed using our innovative reCHEMbinant platform, HeloMYC represents a breakthrough in addressing an ""undruggable"" intracellular target, combining the specificity of protein therapeutics with enhanced cell penetration and stability. MYC, implicated in over 50% of human cancers, has long been considered an elusive target due to its complex protein-protein and protein-nucleic acid interactions and lack of druggable pockets. HeloMYC is a protein based MYC inhibitor that overcomes these challenges and through strategic chemical modifications achieves potent intracellular activity against MYC-driven transcription in cancer cells in preliminary studies. This 18 months project will focus on three key objectives: advancing HeloMYC's preclinical development; expanding and fortifying our IP portfolio to secure a strong market position; and developing a comprehensive commercialization strategy, evaluating spin-off and licensing pathways. The MYSTIC project has the potential to not only provide a powerful new tool against MYC-driven cancers but also to validate a novel approach to developing protein therapeutics against intracellular targets. Success could open new avenues for treating a wide range of diseases with previously undruggable targets, representing a paradigm shift in drug development. By bridging the gap between academic innovation and clinical application, MYSTIC aims to bring hope to millions of cancer patients worldwide and establish a new frontier in precision medicine."

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITEIT LEIDEN
Net EU contribution
€ 150 000,00
Address
RAPENBURG 70
2311 EZ Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)